Treatment response among patients with PR3-AAV who received RTX versus patients with PR3-AAV who received CYC/AZA
| OR* | 95% CI | p Value | |
|---|---|---|---|
| All patients with PR3-AAV (n=131)† | |||
| CR at 6 months | 2.11 | 1.04 to 4.30 | 0.04 |
| CR at 12 months | 1.96 | 0.95 to 4.05 | 0.07 |
| CR at 18 months | 1.44 | 0.68 to 3.05 | 0.34 |
| Patients with PR3-AAV with relapsing disease at baseline (n=81)‡ | |||
| CR at 6 months | 3.57 | 1.43 to 8.93 | <0.01 |
| CR at 12 months | 4.32 | 1.53 to 12.15 | <0.01 |
| CR at 18 months | 3.06 | 1.05 to 8.97 | 0.04 |
*Comparison of RTX group versus CYC/AZA group.
†Covariates included in the model: treatment (RTX or CYC/AZA), age, sex and status of relapsing versus new onset disease at baseline.
‡Covariates included in the model: treatment (RTX or CYC/AZA), age and sex.
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; AZA, azathioprine; CR, complete remission; CYC, cyclophosphamide; PR3, proteinase 3; RTX, rituximab.